These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 2500307)

  • 1. Pathogenesis of the pseudomonas lung lesion in cystic fibrosis.
    Fick RB
    Chest; 1989 Jul; 96(1):158-64. PubMed ID: 2500307
    [No Abstract]   [Full Text] [Related]  

  • 2. Strategies of Pseudomonas aeruginosa to colonize and to persist in the cystic fibrosis lung.
    Kubesch P; Lingner M; Grothues D; Wehsling M; Tümmler B
    Scand J Gastroenterol Suppl; 1988; 143():77-80. PubMed ID: 3133755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of mutant CFTR in hypersusceptibility of cystic fibrosis patients to lung infections.
    Pier GB; Grout M; Zaidi TS; Olsen JC; Johnson LG; Yankaskas JR; Goldberg JB
    Science; 1996 Jan; 271(5245):64-7. PubMed ID: 8539601
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pseudomonas aeruginosa in cystic fibrosis: pathogenesis and persistence.
    Davies JC
    Paediatr Respir Rev; 2002 Jun; 3(2):128-34. PubMed ID: 12297059
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathophysiology and management of pulmonary infections in cystic fibrosis.
    Gibson RL; Burns JL; Ramsey BW
    Am J Respir Crit Care Med; 2003 Oct; 168(8):918-51. PubMed ID: 14555458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathogenesis of respiratory infections and host defenses.
    Zeiher BG; Hornick DB
    Curr Opin Pulm Med; 1996 May; 2(3):166-73. PubMed ID: 9363135
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Mucoid Pseudomonas aeruginosa infection in cystic fibrosis].
    Amitani R; Kuze F
    Nihon Rinsho; 1991 Oct; 49(10):2312-6. PubMed ID: 1749087
    [No Abstract]   [Full Text] [Related]  

  • 8. Pseudomonas aeruginosa infection and humoral antibody response of patients with cystic fibrosis.
    Neter E
    J Infect Dis; 1974 Nov; 130 Suppl(0):S132-3. PubMed ID: 4213765
    [No Abstract]   [Full Text] [Related]  

  • 9. The patterns of infection in cystic fibrosis.
    McCrae WM; Raeburn JA
    Scott Med J; 1974 Jul; 19(4):187-90. PubMed ID: 4210115
    [No Abstract]   [Full Text] [Related]  

  • 10. Emergence and persistence of Pseudomonas aeruginosa in the cystic fibrosis airway.
    Fick RB; Sonoda F; Hornick DB
    Semin Respir Infect; 1992 Sep; 7(3):168-78. PubMed ID: 1475541
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A small molecule neutrophil elastase inhibitor, KRP-109, inhibits cystic fibrosis mucin degradation.
    Chillappagari S; Müller C; Mahavadi P; Guenther A; Nährlich L; Rosenblum J; Rubin BK; Henke MO
    J Cyst Fibros; 2016 May; 15(3):325-31. PubMed ID: 26526358
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical implications of Pseudomonas aeruginosa location in the lungs of patients with cystic fibrosis.
    Moore JE; Mastoridis P
    J Clin Pharm Ther; 2017 Jun; 42(3):259-267. PubMed ID: 28374433
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pulmonary infections in cystic fibrosis: pathogenesis and therapy].
    Götz M
    Monatsschr Kinderheilkd; 1985 Oct; 133(10):718-25. PubMed ID: 3934527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prophylactic antibiotics in cystic fibrosis: a conviction without evidence?
    Smyth A
    Pediatr Pulmonol; 2005 Dec; 40(6):471-6. PubMed ID: 16200640
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Maintaining normal lung function in children with cystic fibrosis is possible with aggressive treatment regardless of Pseudomonas aeruginosa infections.
    Hansen CR; Gilljam M; Olesen HV; Høiby N; Karpati F; Johansson E; Krantz C; Skov M; Pressler T; Lindblad A
    Acta Paediatr; 2021 Sep; 110(9):2607-2609. PubMed ID: 33866605
    [No Abstract]   [Full Text] [Related]  

  • 16. Bacterial flora of respiratory tract in patients with cystic fibrosis, 1950-71.
    Mearns MB; Hunt GH; Rushworth R
    Arch Dis Child; 1972 Dec; 47(256):902-7. PubMed ID: 4630477
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The potential of phage therapy in cystic fibrosis: Essential human-bacterial-phage interactions and delivery considerations for use in Pseudomonas aeruginosa-infected airways.
    Trend S; Fonceca AM; Ditcham WG; Kicic A; Cf A
    J Cyst Fibros; 2017 Nov; 16(6):663-670. PubMed ID: 28720345
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pseudomonas aeruginosa in cystic fibrosis: pathogenesis and new treatments.
    Brugha RE; Davies JC
    Br J Hosp Med (Lond); 2011 Nov; 72(11):614-9. PubMed ID: 22083001
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pulmonary disease associated with Pseudomonas aeruginosa in cystic fibrosis: current status of the host-bacterium interaction.
    Pier GB
    J Infect Dis; 1985 Apr; 151(4):575-80. PubMed ID: 3919113
    [No Abstract]   [Full Text] [Related]  

  • 20. The treatment of respiratory pseudomonas infection in cystic fibrosis: what drug and which way?
    Banerjee D; Stableforth D
    Drugs; 2000 Nov; 60(5):1053-64. PubMed ID: 11129122
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.